全文获取类型
收费全文 | 26864篇 |
免费 | 1927篇 |
国内免费 | 168篇 |
专业分类
耳鼻咽喉 | 109篇 |
儿科学 | 1508篇 |
妇产科学 | 617篇 |
基础医学 | 2331篇 |
口腔科学 | 113篇 |
临床医学 | 2724篇 |
内科学 | 8210篇 |
皮肤病学 | 481篇 |
神经病学 | 2085篇 |
特种医学 | 247篇 |
外科学 | 3035篇 |
综合类 | 697篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2356篇 |
眼科学 | 960篇 |
药学 | 1173篇 |
2篇 | |
中国医学 | 53篇 |
肿瘤学 | 2251篇 |
出版年
2024年 | 41篇 |
2023年 | 252篇 |
2022年 | 235篇 |
2021年 | 360篇 |
2020年 | 357篇 |
2019年 | 125篇 |
2018年 | 483篇 |
2017年 | 510篇 |
2016年 | 564篇 |
2015年 | 555篇 |
2014年 | 459篇 |
2013年 | 736篇 |
2012年 | 2069篇 |
2011年 | 2403篇 |
2010年 | 837篇 |
2009年 | 801篇 |
2008年 | 2510篇 |
2007年 | 2404篇 |
2006年 | 2076篇 |
2005年 | 2179篇 |
2004年 | 2181篇 |
2003年 | 2187篇 |
2002年 | 1747篇 |
2001年 | 1285篇 |
2000年 | 309篇 |
1999年 | 157篇 |
1998年 | 212篇 |
1997年 | 121篇 |
1996年 | 92篇 |
1995年 | 66篇 |
1994年 | 82篇 |
1993年 | 39篇 |
1992年 | 50篇 |
1991年 | 35篇 |
1990年 | 50篇 |
1989年 | 43篇 |
1988年 | 41篇 |
1987年 | 43篇 |
1986年 | 44篇 |
1985年 | 32篇 |
1984年 | 31篇 |
1983年 | 13篇 |
1982年 | 18篇 |
1981年 | 20篇 |
1980年 | 12篇 |
1979年 | 14篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1970年 | 8篇 |
1928年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Masafumi Fukagawa Keitaro Yokoyama Fumihiko Koiwa Masatomo Taniguchi Tetsuo Shoji Junichiro James Kazama Hirotaka Komaba Ryoichi Ando Takatoshi Kakuta Hideki Fujii Msasaaki Nakayama Yugo Shibagaki Seiji Fukumoto Naohiko Fujii Motoshi Hattori Akira Ashida Kunitoshi Iseki Takashi Shigematsu Yusuke Tsukamoto Yoshiharu Tsubakihara Tadashi Tomo Hideki Hirakata Tadao Akizawa CKD‐MBD Guideline Working Group Japanese Society for Dialysis Therapy 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2013,17(3):247-288
992.
原发性肝癌规范化诊治的专家共识 总被引:1,自引:0,他引:1
一、前言
原发性肝癌(PLC)是临床上最常见的恶性肿瘤之一,全球发病率逐年增长,已超过62.6万/年,居于恶性肿瘤的第5位;死亡接近60万/年,位居肿瘤相关死亡的第3位.PLC在我国高发,目前,我国患者数约占全球的55%;在肿瘤相关死亡中仅次于肺癌,位居第二.因此,肝癌严重威胁我国人民健康和生命. 相似文献
993.
Prognosis Assessment of Cardiac Involvement in Systemic AL Amyloidosis by Magnetic Resonance Imaging
Arsene Mekinian Christophe Lions Xavier Leleu Alain Duhamel Nicolas Lamblin Valerie Coiteux Pascal De Groote Pierre-Yves Hatron Thierry Facon Jean-Paul Beregi Eric Hachulla David Launay Lille Amyloidosis Study Group 《The American journal of medicine》2010,123(9):864-868
Background
Cardiac involvement is one of the most important prognostic factors in systemic AL amyloidosis. The aim of our study was to assess the role of cardiovascular magnetic resonance (CMR) imaging in prognosis evaluation in AL amyloidosis.Methods
We retrospectively analyzed 29 consecutive patients with AL amyloidosis who had undergone CMR. Clinical, laboratory, echocardiographic, and CMR characteristics were compared between CMR-positive (ie, with CMR signs of cardiac localization of AL amyloidosis) and CMR-negative patients. Univariate and multivariate analyses were performed to assess the prognostic value of positive CMR in comparison with other prognostic factors.Results
CMR was positive in 11 patients (38%). The overall survival rates for CMR-positive patients were 28%, 14%, and 14% versus 84%, 77%, and 45% at 1, 2, and 5 years, respectively, for CMR-negative patients (P = .002). Late gadolinium enhancement patterns, biventricular hypertrophy, and pericardial effusion on CMR were more frequent in nonsurvivors. Congestive heart failure, abnormal echocardiography, Eastern Cooperative Oncology Group grade >1, brain natriuretic peptide, and left ventricular ejection fraction <55% also were associated with a decreased survival. The presence of congestive heart failure was the only significant variable associated with survival on multivariate analysis.Conclusion
We found that the presence of a positive CMR in AL amyloidosis was associated with a significantly increased risk of death, in particular of cardiac origin, but was not independent of clinical congestive heart failure. 相似文献994.
中国输血协会临床输血学专业委员会 《中国临床新医学》2022,15(1):1-5
产后出血(PPH)是产科的危重症,需要通过患者血液管理(PBM)改善预后。中国输血协会临床输血学专业委员会制订了PPH的PBM专家共识(2022年版)。该共识强调PBM一定要基于PPH正确处理的基础上。该共识重视血小板和凝血因子的功能和数量的管理,明确了多种情况下血小板和新鲜冰冻血浆等的输注指征。该共识还明确提出了实施大量输血程序的办法。 相似文献
995.
Scott R. Bauer MD ScM Peggy M. Cawthon PhD MPH Kristine E. Ensrud MD Anne M. Suskind MD MS John C. Newman MD PhD Howard A. Fink MD MPH Kaiwei Lu MS Rebecca Scherzer PhD Andrew R. Hoffman MD Kenneth Covinsky MD Lynn M. Marshall ScD For the Osteoporotic Fractures in Men Research Group 《Journal of the American Geriatrics Society》2022,70(4):1082-1094
996.
Batyraliev TA Pershukov IV Niyazova-Karben ZA Karaus A Calenici O Guler N Eryonucu B Temamogullari A Ozgul S Akgul F Sengul H Dogru O Demirbas O Timoshin IS Gaigukov AV Petrakova LN Peresypko MK Sidorenko BA;International Invasive Cardiology Research Group 《Angiology》2006,57(1):21-32
Treatment of in-stent restenosis (ISR) with conventional percutaneous transluminal coronary angioplasty (PTCA) causes significant recurrent neointimal tissue growth in 30-85%. Therefore, laser ablation of intrastent neointimal hyperplasia before balloon dilation can be an attractive alternative. However, the long-term outcomes of such treatment have not been studied thoroughly enough. This prospective case-control study evaluated angiographic and clinical outcomes of PTCA alone and a combination of excimer laser coronary angioplasty (ELCA) and adjunct PTCA in 125 patients with ISR. ELCA was performed before balloon dilation in 67 patients, PTCA alone was performed in 58 patients. Basic demographic and clinical data were comparable in both groups. Lesions included in ELCA group were longer (17.1+/-9.9 vs 13.6+/-9.1 mm; p = 0.034), more complex (36.5% type C stenoses vs 14.3%; p = 0.006), and more frequently had reduced distal blood flow (TIMI <3: 18.9% vs 4.8%; p = 0.025) compared to lesions in the PTCA group. Immediate angiographic results of PTCA and ELCA + PTCA appeared to be comparable. PTCA alone was successful in 57 patients (98.3%), ELCA + PTCA, in 66 patients (98.5%). The rates of hospital complications were comparable (3.0% in ELCA group vs 8.6% in PTCA group). The 1-year follow-up showed that the rates of major adverse cardiac events (MACE) were comparable in the 2 groups (37.3% in ELCA group vs 46.6% in PTCA group). The rates of target vessel revascularization (TVR) within 1 year after the intervention were also similar in the 2 groups (32.8% vs 34.5%). The data mean that ELCA in patients with complex ISR is efficient and safe. Despite a higher complexity of lesions in the ELCA group, no increase in the rate of complications was registered. 相似文献
997.
Wartelle-Bladou C Arpurt JP Renou C Pariente A Pillon D Nalet B Picon M Glibert A Chousterman M Grasset D Morin T Bernard P Fischer D Ramdani M Lagier E Rotily M;Viral Hepatitis Group of the ANGH 《Gastroentérologie clinique et biologique》2006,30(4):525-532
OBJECTIVES: To evaluate in naive patients with chronic hepatitis C 1- the efficacy and safety of one month interferon alpha (IFN-alpha) induction regimen; 2- the potential virological benefit of a secondary adjunction of ribavirin among HCV RNA negative patients after 20 weeks of IFN therapy, with or without an initial 4-week IFN induction. MATERIAL AND METHODS: 151 naive HCV-RNA positive patients presenting with biopsy- proven chronic hepatitis C and elevated ALT were randomised in a 2: 1 ratio in two arms: IFN-alpha 3 MU thrice a week (tiw) for 24 weeks (non-induced patients); IFN-alpha 6 MU daily for two weeks, then 3 MU daily for two weeks then 3 MU tiw for 20 weeks (induced patients). At week 24, HCV-RNA negative patients were randomised to receive in addition or not ribavirin 1-1.2 g daily for 24 additional weeks. Induction efficacy was assessed on the early viral response (EVR) defined as undetectable HCV RNA at week 4 then week 20. Ribavirin efficacy was assessed on the proportion of maintained complete response until the end of follow-up, 24 weeks after discontinuation of treatment. Data were analysed on an intent-to-treat basis. RESULTS: Efficacy of IFN-alpha induction: 104 patients were randomised to the non-induction group, 47 to the induction group. Gender, age, genotype distribution and HCV viral load at baseline did not differ significantly between the two groups. There was one treatment discontinuation because of adverse events in induced patients versus four in non-induced patients (P > 0.05). The 4 week EVR was significantly greater in induced patients in patients with HCV genotype 1, 4 or 5 (47% vs 12%, P=0.0002) only. There was no impact of induction in patients with HCV genotype 2 or 3. Efficacy of ribavirin: at week 24, 28 and 26 HCV-RNA negative patients were randomised to addition of ribavirin or not, respectively. Patients randomised to secondary additive ribavirin were more often HCV-RNA negative at the end of follow-up than patients treated with IFN-alpha alone: 18/28 (64%) vs 10/26 (39%); P=0.06. Among patients randomised to bitherapy, the relapse rate was significantly lower in patients with genotype 2 or 3 (0/12 vs 6/13, P=0.01) and not in those with genotype 1, 4 or 5 (5/11 vs 3/6, P=0.99). CONCLUSION: A 4 week IFN-alpha induction significantly increases the EVR rate in patients with HCV genotype 1, 4 or 5. Late secondary adjunction of ribavirin to IFN-alpha for 6 months in HCV-RNA negative patients after 6 months of IFN-alpha significantly decreases the relapse rate in patients with HCV genotype 2 or 3, but not in patients with genotypes 1, 4 or 5. 相似文献
998.
Norgren L Jawien A Mátyás L Riegerd H Arita K;European MCI- Study Group 《Vascular medicine (London, England)》2006,11(2):75-83
This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent claudication. Following a single-blind placebo run-in period of 6 weeks, 364 (309 male and 55 female) patients (59.2 +/- 8.4 years, mean +/- SD) were randomized to receive sarpogrelate 200 mg bid, 200 mg tid or placebo for 24 weeks with a follow-up of 8 weeks. The primary objective was the increase of absolute claudication distance (ACD) at the end of treatment (week 24) compared to placebo. Analysis of covariance (ANCOVA) was performed on the log-transformed percentage of baseline ACD: loge(ACD/baseline). A responder analysis (defined as a > or = 50% improvement in ACD) was also performed. There was a marked training/placebo effect on the ACD which persisted up to 16 weeks. At 24 weeks the primary objective did not reach statistical significance (200mg bid vs placebo, p = 0.225; 200mg tid vs placebo, p = 0.580). In the responder analysis, 200 mg bid showed a statistically significant difference vs placebo (p = 0.035). In the exploratory analysis with completers (patients completing all treadmill tests), there was a statistical difference in ACD/baseline change for 200 mg bid (p = 0.035) and in the responder analysis for 200 mg tid (p = 0.044) at 24 weeks compared to placebo. Both treatments showed a carry-over effect for ACD during the 8-week follow-up (weeks 28-32). The treatment was well tolerated and no clinically significant safety concerns were reported. In conclusion, the study results confirm that sarpogrelate is well tolerated and although the primary endpoint failed to reach statistical significance, the responder analysis showed an increased absolute walking distance, which makes a further trial warranted, including a larger population, and possibly also a longer treatment period. 相似文献
999.
Gordin D Hiilesmaa V Fagerudd J Rönnback M Forsblom C Kaaja R Teramo K Groop PH;FinnDiane Study Group 《Diabetologia》2007,50(3):516-522
Aims/hypothesis Our aim was to study whether pre-eclampsia and pregnancy-induced hypertension are predictors of diabetic nephropathy in type
1 diabetic women.
Materials and methods A total of 203 type 1 diabetic women, who were pregnant between 1988 and 1996 and followed at the Department of Obstetrics
and Gynaecology in Helsinki, were re-assessed after an average of 11 years within the nationwide, multi-centre Finnish Diabetic
Nephropathy Study. Diabetic nephropathy was defined as microalbuminuria, macroalbuminuria or end-stage renal disease.
Results Patients with prior pre-eclampsia had diabetic nephropathy more often than patients with a normotensive pregnancy (diabetic
nephropathy vs normal albumin excretion rate: 41.9% vs 8.9%; p<0.001), whereas patients with a history of pregnancy-induced hypertension did not (10.3% vs 8.9%; p=0.81). CHD was more prevalent in patients with a history of pre-eclampsia than in patients with a normotensive pregnancy
(12.2% vs. 2.2%; p=0.03). Pre-eclampsia (odds ratio [OR] 7.7, 95% CI 1.6-36.1; p=0.01) and HbA1c (OR 2.0, 95% CI 1.1-3.8; p<0.05) were associated with incident diabetic nephropathy even when adjusted for follow-up time, BMI, smoking, diabetes duration
and age.
Conclusions/interpretation These data suggest that a history of pre-eclamptic pregnancy but not pregnancy-induced hypertension is associated with an
elevated risk of diabetic nephropathy.
Electronic supplementary material Supplementary material is available in the online version of this article at and is accessible to authorised users. 相似文献
1000.
Luis Bujanda Cristina Sarasqueta Elisabeth Hijona Lander Hijona Angel Cosme Ines Gil Jose Luis Elorza Jose I Asensio Santiago Larburu José M Enríquez-Navascués Rodrigo Jover Francesc Balaguer Xavier Llor Xavier Bessa Montserrat Andreu Artemio Paya Antoni Castells Gastrointestinal Oncology Group of the Spanish Gastroenterological Association 《World journal of gastroenterology : WJG》2010,16(7):862-867
AIM:To evaluate changes in colorectal cancer(CRC) survival over the last 20 years.METHODS:We compared two groups of consecutive CRC patients that were prospectively recruited:Group Ⅰincluded 1990 patients diagnosed between 1980 and 1994.GroupⅡincluded 871 patients diagnosed in 2001.RESULTS:The average follow up time was 21 mo(1-229)for GroupⅠand 50 mo(1-73.4)for GroupⅡ.Overall median survival was significantly longer in Group Ⅱthan in GroupⅠ(73 mo vs 25 mo,P<0.001)and the difference was significant for all ... 相似文献